Ligand for herpes simplex virus entry mediator and methods of use
View Patent ↗A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. LIGHT is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpesvirus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases, inflammatory disorders or those having or suspected of having a herpesvirus infection, utilizing p30 and the fusion proteins of the invention, are also provided.
1. A method for treating a subject having a CMV infection comprising contacting the subject with an amount of an agonist antibody or antigen binding fragment thereof that binds to lymphotoxin beta receptor (LTβR) sufficient to treat the CMV infection.
2. The method of claim 1 , wherein the antibody is fully human.
3. The method of claim 1 , wherein the antibody is humanized.
4. The method of claim 1 , wherein CMV proliferation is reduced in the subject following treatment.
5. The method of claim 1 , wherein CMV nucleic acid replication is reduced in the subject following treatment.
6. The method of claim 1 , wherein the CMV infection is due to CMV reactivation from latency.
7. The method of claim 1 , wherein the subject is immunosuppressed.
8. The method of claim 7 , wherein the immunosuppression is due to HIV infection.
9. The method of claim 7 , wherein the immunosuppression is due to a blood or bone marrow, organ, or tissue transplant.
10. The method of claim 1 , wherein the subject is a neonate.
11. The method of claim 1 , wherein the agonist antibody does not function by inducing death of cells infected with the CMV.
12. The method of claim 1 , further comprising contacting the subject with an antiviral agent.
13. The method of claim 1 , wherein said method comprises contacting the subject with an amount of said antigen binding fragment thereof sufficient to treat the CMV infection.
14. The method of claim 1 , wherein the antibody is in a pharmaceutical composition.
15. A method for treating a subject having a CMV infection due to immuno suppression or reactivation of CMV from latency, comprising contacting the subject with an amount of an agonist antibody or antigen binding fragment thereof that binds to lymphotoxin beta receptor (LTβR) sufficient to treat CMV infection due to immunosuppression or reactivation of CMV from latency.
16. The method of claim 15 , wherein the antibody is fully human.
17. The method of claim 15 , wherein the antibody is humanized.
18. The method of claim 15 , wherein CMV proliferation is reduced in the subject following treatment.
19. The method of claim 15 , wherein CMV nucleic acid replication is reduced in the subject following treatment.
20. The method of claim 15 , wherein the immunosuppression is due to HIV infection.
21. The method of claim 15 , wherein the immunosuppression is due to a blood or bone marrow, organ, or tissue transplant.
22. The method of claim 15 , wherein the subject is a neonate.
23. The method of claim 15 , wherein the agonist antibody does not function by inducing death of cells infected with the virus.
24. The method of claim 15 , further comprising contacting the subject with an antiviral agent.
25. The method of claim 15 , wherein said method comprises contacting the subject with an amount of said antigen binding fragment thereof sufficient to treat the CMV infection due to immunosuppression or reactivation of CMV from latency.
26. The method of claim 15 , wherein the antibody is in a pharmaceutical composition.
27. The method of claim 1 , wherein the CMV infection is selected from CMV hepatitis, CMV retinitis, CMV pneumonitis and CMV nephritis.
28. The method of claim 1 , wherein CMV protein expression is reduced in the subject following treatment.
29. The method of claim 15 , wherein CMV protein expression is reduced in the subject following treatment.
30. The method of claim 7 , wherein the immunosuppression is due to a tumor.
31. The method of claim 15 , wherein the immunosuppression is due to a tumor.